Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Cooper ZA, et al. Among authors: juneja vr. Cancer Immunol Res. 2014 Jul;2(7):643-54. doi: 10.1158/2326-6066.CIR-13-0215. Epub 2014 Apr 29. Cancer Immunol Res. 2014. PMID: 24903021 Free PMC article.
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.
Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC Jr, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T. Kleffel S, et al. Among authors: juneja vr. Cell. 2015 Sep 10;162(6):1242-56. doi: 10.1016/j.cell.2015.08.052. Cell. 2015. PMID: 26359984 Free PMC article.
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN. Manguso RT, et al. Among authors: juneja vr. Nature. 2017 Jul 27;547(7664):413-418. doi: 10.1038/nature23270. Epub 2017 Jul 19. Nature. 2017. PMID: 28723893 Free PMC article.
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. Mooradian MJ, et al. Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018. Oncoimmunology. 2018. PMID: 29721378 Free PMC article.
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance.
Tan CL, Kuchroo JR, Sage PT, Liang D, Francisco LM, Buck J, Thaker YR, Zhang Q, McArdel SL, Juneja VR, Lee SJ, Lovitch SB, Lian C, Murphy GF, Blazar BR, Vignali DAA, Freeman GJ, Sharpe AH. Tan CL, et al. Among authors: juneja vr. J Exp Med. 2021 Jan 4;218(1):e20182232. doi: 10.1084/jem.20182232. J Exp Med. 2021. PMID: 33045061 Free PMC article.
19 results